Generating the Right Evidence to Fuel Funding in Pharmaceutical Innovation

Capital investment is the life blood of pharmaceutical innovation, and it is critical for driving research and development (R&D) and accelerating commercial success for the life sciences industry.

However, attracting the necessary capital is challenging as investors have a plethora of options to choose from in a highly competitive marketplace when making investment decisions. Additionally, financial analysts are more inquisitive than ever when making their recommendations. Having access to and utilizing the right clinical and commercial evidence is a prerequisite for attracting capital funding and investments to secure commercial success. Many mistakes are made, for example, when the wrong data is chosen, overly optimistic market assumptions about market size are developed, or forecasting overlooks the impact of rigorous payer control.

Download the white paper to learn more!